Diagnosis, treatment and prevention of severe acute respiratory syndrome coronavirus 2 infection in children: experts′ consensus statement (Fifth Edition)updated for the Omicron variant
- VernacularTitle:儿童新型冠状病毒感染诊断、治疗和预防专家共识(第五版)
- Author:
Rongmeng JIANG
1
;
Zhengde XIE
;
Yi JIANG
;
Xiaoxia LU
;
Runming JIN
;
Yuejie ZHENG
;
Yunxiao SHANG
;
Baoping XU
;
Zhisheng LIU
;
Gen LU
;
Jikui DENG
;
Guanghua LIU
;
Xiaochuan WANG
;
Jianshe WANG
;
Luzhao FENG
;
Wei LIU
;
Yi ZHENG
;
Sainan SHU
;
Min LU
;
Wanjun LUO
;
Miao LIU
;
Yuxia CUI
;
Leping YE
;
Adong SHEN
;
Gang LIU
;
Liwei GAO
;
Lijuan XIONG
;
Yan BAI
;
Likai LIN
;
Zhuang WEI
;
Fengxia XUE
;
Tianyou WANG
;
Dongchi ZHAO
;
Zhengyan ZHAO
;
Jianbo SHAO
;
Wong Wing-kin GARY
;
Yanxia HE
;
Xingwang LI
;
Yonghong YANG
;
Kunling SHEN
Author Information
- Keywords: Severe acute respiratory syndrome coronavirus 2 infection; Child; Omicron variant; Diagnosis; Treatment; Prevention; Consensus
- From: Chinese Journal of Applied Clinical Pediatrics 2023;38(1):20-30
- CountryChina
- Language:Chinese
- Abstract: China has classified the Corona Virus Disease 2019(COVID-19) as a statutory category B infectious disease and managed it according to Category B since January 8, 2023.In view that Omicron variant is currently the main epidemic strain in China, in order to guide the treatment of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) infection in children with the times, refer to the Diagnosis and Treatment Protocol for Novel Coronavirus Infection (Trial 10 th Edition), Expert Consensus on Diagnosis, Treatment and Prevention of Novel Coronavirus Infection in Children (Fourth Edition) and the Diagnosis and Treatment Strategy for Pediatric Related Viral Infections.The Expert Consensus on the Diagnosis, Treatment and Prevention of Novel Coronavirus Infection in Children (Fifth Edition) has been formulated and updated accordingly on related etiology, epidemiology, pathogenic mechanism, clinical manifestations, auxiliary examination, diagnosis and treatment, and added key points for the treatment of COVID-19 related encephalopathy, fulminating myocarditis and other serious complications for clinical reference.
